Esophageal Cancer Clinical Trials

• Signed written informed consent and voluntarily agrees to participate in the study.

• Histologically or cytologically confirmed esophageal squamous cell carcinoma (ESCC).

• Thoracic esophageal cancer evaluated by CT, MRI, or EUS, with clinical stage T1b-T2N+ or T3-T4a, any N (according to the AJCC 8th edition).

• Expected to achieve R0 resection after neoadjuvant therapy.

• Age between 18 and 75 years, male or female.

• \*\*ECOG performance status of 0-1.

• No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, or surgery.

• Planned to undergo surgical resection after completion of neoadjuvant therapy.

• No contraindications to surgery.

⁃ Adequate organ function, defined as follows:

⁃ a) Hematology (without the use of any blood components, hematopoietic growth factors, leukocyte or platelet stimulants, or anemia-correcting agents within 14 days before first study drug administration):

⁃ \* Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L

⁃ \* Platelet count ≥ 100 × 10⁹/L

‣ Hemoglobin ≥ 90 g/L b) Serum biochemistry:

‣ Total bilirubin ≤ 1.5 × ULN

‣ ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN

‣ Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min c) Coagulation:

‣ INR ≤ 1.5 × ULN

‣ APTT ≤ 1.5 × ULN

⁃ Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to first dosing and must agree to use effective contraception (such as intrauterine device, oral contraceptives, or condoms) during the study and for at least 3 months after the last dose.Male participants with partners of childbearing potential must be surgically sterile or agree to use effective contraception during the study and for 3 months after the last dose.

⁃ Good compliance and willingness to adhere to study visits and follow-up requirements.